Regulatory Milestones

Alpha Cognition Inc. Advances Alzheimer's Treatment with ZUNVEYL, Secures Key Regulatory Milestones

Alpha Cognition Inc. reports significant progress in the commercialization of ZUNVEYL for Alzheimer's disease, highlighting early adoption in the U.S. long-term care market and a key regulatory achievement in China.